Compass Therapeutics, Inc. CMPX NASDAQ

Compass Therapeutics, Inc. (CMPX) reported total assets of $219.59M and total liabilities of $22.8M for quarter ending 2025-12-31, resulting in total equity of $196.79M.

The company held $208.91M in cash and short-term investments. Total debt stood at $9.83M, with net debt of $-20.81M. The Debt-to-Equity (D/E) ratio was 0.05 (conservative).

Current ratio is 15.02, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.05, current ratio of 15.02 — balance sheet is strong
• MOAT (52/100) — Total assets $219.59M and equity $196.79M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.05 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 59/100 with 3/7 criteria passed.